[Microinflammation in the pathogenesis of diabetic nephropathy].
Shikata
Kenichi
K
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation / Q000150:complications*; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007668:Kidney / Q000276:immunology; D008262:Macrophage Activation; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045162:Thiazolidinediones; D018799:Intercellular Adhesion Molecule-1; D000077205:Pioglitazone